Closing the Gap: Advancing Precision Oncology Through Education and Collaboration
How top-to-bottom collaboration can alleviate hurdles and help increase equitable access to the most effective treatments for all cancer patients.
Kathy Davy
Kathy Davy is the President of Clinical Next-Generation Sequencing at Thermo Fisher Scientific. She completed her BS in Biology from the University of California, Irvine and MBA from The Fuqua School of Business at Duke University. Prior to joining Thermo Fisher, Kathy held roles at several other prominent organizations in the industry. Her expertise spans across pharmaceuticals and companion diagnostics, molecular diagnostics, cancer genomics, and next-generation sequencing. She is passionate about driving forward innovation in precision oncology to bridge the gap between research and practice.